Home pagePTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Chiusura precedente
19,50 $
Intervallo annuale
11,44 $ - 23,73 $
Cap di mercato
72,33 Bln IDR
Volume medio
138,00
Notizie del mercato finanziario
OSPTX
0,61%
Dati finanziari
Conto economico
Entrate
Utile netto
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Entrate | 8,85 Bln | 5,77% |
Spese di gestione | 2,24 Bln | 9,58% |
Utile netto | 1,08 Bln | 12,45% |
Margine di profitto netto | 12,17 | 6,29% |
Utili per azione | 23,57 | 13,86% |
EBITDA | 1,57 Bln | 11,60% |
Aliquota fiscale effettiva | 22,83% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 4,69 Bln | 10,74% |
Totale attivo | 30,58 Bln | 5,59% |
Totale passivo | 5,22 Bln | 7,63% |
Patrimonio netto totale | 25,36 Bln | — |
Azioni in circolazione | 45,65 Mld | — |
Prezzo/valore contabile | 0,04 | — |
Redditività dell'attivo | 11,54% | — |
Rendimento sul capitale | 13,57% | — |
Flusso di cassa
Flusso di cassa netto
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Utile netto | 1,08 Bln | 12,45% |
Liquidità di esercizio | 344,56 Mld | -71,44% |
Contanti da investimenti | -118,66 Mld | 61,24% |
Contanti da finanziamenti | -423,13 Mld | -791,88% |
Flusso di cassa netto | -180,46 Mld | -121,28% |
Flusso di cassa libero | -102,67 Mld | -114,36% |
Informazioni
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Fondazione
10 set 1966
Sito web
Dipendenti
12.841